JARKKO RAUTIO

Yhteystiedot

Avainsanat

Opetustehtävät

Yhteiskunnalliset tehtävät

Tutkimusryhmät ja -projektit

Tutkimusryhmät

• Aihiolääketutkimusryhmä

• LinkedIn LinkedIn
• Research gate Research gate
• Orcid Orcid

Julkaisut

• Gütschow, Michael; Eynde, Jean Jacques Vanden; Jampilek, Josef; Kang, CongBao; Mangoni, Arduino A; Fossa, Paola; Karaman, Rafik; Trabocchi, Andrea; Scott, Peter JH; Reynisson, Jóhannes; Rapposelli, Simona; Galdiero, Stefania; Winum, Jean-Yves; Brullo, Chiara; Prokai-Tatrai, Katalin; Sharma, Arun K; Schapira, Matthieu; Azuma, Yasu-Taka; Cerchia, Laura; Spetea, Mariana; et al. incl. Rautio, J. 2020. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7 Molecules 25 13: E2968. 2020
• Matovic, Jelena; Järvinen, Juulia; Bland, Helena C; Sokka, Iris K; Imlimthan, Surachet; Ferrando, Ruth Mateu; Huttunen, Kristiina M; Timonen, Juri; Peräniemi, Sirpa; Aitio, Olli; Airaksinen, Anu J; Sarparanta, Mirkka; Johansson, Mikael P; Rautio, Jarkko; Ekholm, Filip S. 2020. Addressing the biochemical foundations of a glucose-based "Trojan horse"-stradegy to boron neutron capture therephy: from chemical synthesis to in vitro assesment Molecular pharmaceutics 17 10: 3885-3899. 2020
• Pocasap, P; Weerapreeyakul, N; Timonen, J; Järvinen, J; Leppänen, J; Kärkkäinen, J; Rautio, J. 2020. Tyrosine-chlorambucil conjugates facilitate cellular uptake through L-type amino acid transporter 1 (LAT1) in human breast cancer cell line MCF-7 International journal of molecular sciences 21 6: 2132. 2020
• Heikkinen, Emma M; Ruponen, Marika; Jasper, Lisa-Marie; Leppänen, Jukka; Hellinen, Laura; Urtti, Arto; Auriola, Seppo; Rautio, Jarkko; Vellonen, Kati-Sisko. 2020. Prodrug Approach for Posterior Eye Drug Delivery: Synthesis of Novel Ganciclovir Prodrugs and in Vitro Screening with Cassette Dosing Molecular pharmaceutics 17 6: 1945-1953. 2020
• Mangoni, AA; Eynde, JJV; Jampilek, J; Hadjipavlou-Litina, D; Liu, H; Reynisson, J; Sousa, ME; Gomes, PAC; Prokai-Tatrai, K; Tuccinardi, T; Sabatier, JM; Luque, FJ; Rautio, J; Karaman, R; Vasconcelos, MH; Gemma, S; Galdiero, S; Hulme, C; Collina, S; Gütschow, M; et al.. 2019. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-5 Molecules 24 13: 2415. 2019
• Srisongkram, T; Weerapreeyakul, N; Kärkkäinen, J; Rautio, J. 2019. Role of L-Type Amino Acid Transporter 1 (LAT1) for the Selective Cytotoxicity of Sesamol in Human Melanoma Cells Molecules 24 21: 3869. 2019
• Vanden Eynde, JJ; Mangoni, AA; Rautio, J; Leprince, J; Azuma, YT; García-Sosa, AT; Hulme, C; Jampilek, J; Karaman, R; Li, W; Gomes, PAC; Hadjipavlou-Litina, D; Capasso, R; Geronikaki, A; Cerchia, L; Sabatier, JM; Ragno, R; Tuccinardi, T; Trabocchi, A; Winum, JY et al.. 2019. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-6 Molecules 2020; 25 1: 1-24. 2019
• Mangoni, AA; Tuccanardi, T; Collina, S; Vanden Eynde, JJ; Muñoz-Torrero, D; Karaman, R; Siciliano, C; de Sousa, ME; Prokai-Tatrai, K; Rautio, J; Guillou, C; Gütschow, M; Galdiero, S; Liu, H; Agrofoglio, LA; Sabatier, JM; Hulme, C; Kokotos, G; You, Q; Gomes, PAC. 2018. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-3 MOLECULES 23 7: 1596. 2018
• Thiele, Nikki A; Kärkkäinen, Jussi; Sloan, Kenneth B; Rautio, Jarkko; Huttunen, Kristiina M. 2018. Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug Bioorganic and medicinal chemistry letters 28 17: 2856-2860. 2018
• Rautio, Jarkko; Meanwell, Nicholas A; Di, Li; Hageman, Michael J. 2018. The expanding role of prodrugs in contemporary drug design and development NATURE REVIEWS DRUG DISCOVERY 17: 559-587. 2018
• Lukin, Alexey; Kramer, Jan; Hartmann, Markus; Weizel, Lilia; Hernandez- Olmos, Victor; Falahati, Konstantin; Burghardt, Irene; Kalinchenkova, Natalia; Bagnyukova, Darya; Zhurilo, Nikolay; Rautio, Jarkko; Forsberg, Markus; Ihalainen, Jouni; Auriola, Seppo; Leppänen, Jukka; Konstantinov, Igor; Pogoryelov, Denys; Proschak, Ewgenij; Dar'in, Dmitry; Krasavin, Mikhail. 2018. Discovery of Polar Spirocyclic Orally Bioavailable Urea Inhibitors of Soluble Epoxide Hydrolase Bioorganic chemistry 80: 655-667. 2018
• Mangoni, AA; Guillou, C; Vanden Eynde, JJ; Hulme, C; Jampilek, J; Li, W; Prokai-Tatrai, K; Rautio, J; Collina, S; Tuccinardi, T; Sousa, ME; Sabatier, JM; Galdiero, S; Karaman, R; Kokotos, G; Torri, G; Luque, FJ; Vasconcelos, MH; Hadjipavlou-Litina, D; Siciliano, C; et al. 2018. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-4 MOLECULES 24 1: 130. 2018
• Kärkkäinen, J; Gynther, M; Kokkola, T; Petsalo, A; Auriola, S; Lahtela-Kakkonen, M; Laine, K; Rautio, J; Huttunen, KM. 2018. Structural properties for selective and efficient L-type amino acid transporter 1 (LAT1) mediated cellular uptake INTERNATIONAL JOURNAL OF PHARMACEUTICS 544 1: 91-99. 2018
• Aihiolääkkeet. Rautio, Jarkko / Farmakologia ja toksikologia. 2018. 2018
• Muñoz-Torrero D, Mangoni AA, Guillou C, Collina S, Eynde JJV, Rautio J, Keseru GM, Hulme C, Chibale K, Luque FJ, Karaman R, Gütschow M, Liu H, Ragno R. 2017. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes. MOLECULES 22 5: 743. 2017
• Muñoz-Torrero, D; Mangoni, AA; Liu, H; Hulme, C; Rautio, J; Karaman, R; De Sousa, ME; Prokai-Tatrai, K; Sabatier, J-M; Siciliano, C; Luque, FJ; Kokotos, G; Ragno, R; Collina, S; Guillou, C; Gütschow, M; Agrofoglio, LA. 2017. Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-2. MOLECULES 2018; 23 1: 65. 2017
• Rautio Jarkko, Kärkkäinen Jussi, Sloan Kenneth B. 2017. Prodrugs : recent approvals and a glimpse of the pipeline. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 109: 146-161. 2017
• Sangthonga S, Weerapreeyakulb N, Lehtonen M, Leppanen J, Rautio J. 2017. High-accuracy mass spectrometry for identification of sulphur-containing bioactive constituents and flavonoids in extracts of Raphanus sativus var. caudatus Alef (Thai rat-tailed radish). Journal of Functional Foods 31: 237-247. 2017
• Walther Raoul, Rautio Jarkko, Zelikin Alexander N. 2017. Prodrugs in medicinal chemistry and enzyme prodrug therapies. ADVANCED DRUG DELIVERY REVIEWS 118: 65-77. 2017
• Krasavin Mikhail, Lukin Alexey, Bagnyukova Daria, Zhurilo Nikolay, Zahanich Ihor, Zozulya Sergey, Ihalainen Jouni, Forsberg Markus M, Lehtonen Marko, Rautio Jarkko, Moore Daniel, Tikhonova Irina G. 2016. Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835. BIOORGANIC AND MEDICINAL CHEMISTRY 24 21: 5481-5494. 2016
• Gynther Mikko, Peura Lauri, Vernerová Monika, Leppänen Jukka, Kärkkäinen Jussi, Lehtonen Marko, Rautio Jarkko, Huttunen Kristiina M. 2016. Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure. NEUROCHEMICAL RESEARCH 41 10: 2797-2809. 2016
• Ramirez Yulian P, Mladek Ann C, Phillips Roger M, Gynther Mikko, Rautio Jarkko, Ross Alonzo H, Wheelhouse Richard T, Sakaria Jann N. 2014. Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. Molecular Cancer Therapeutics 2015; 14 1: 111-119. 2014
• Rautio Jarkko, Huttunen Kristiina, Gynther Mikko, Laine Krista, Leppänen Jukka, Kärkkäinen Jussi, Malmioja Kalle. 2014. Aihiolääketeknologia lääkekehityksessä. DOSIS : FARMASEUTTINEN AIKAKAUSKIRJA 30 3: 209. 2014
• Rautio Jarkko, Kärkkäinen Jussi, Huttunen Kristiina, Gynther Mikko. 2014. Amino acid ester prodrugs conjugated to the alpha-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1). EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 2015; 66: 36-40. 2014
• Rautio Jarkko, Vernerová Monika, Aufderhaar Imke, Huttunen Kristiina M. 2014. Glutathione-S-transferase selective release of metformin from its sulfonamide prodrug. BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 24 1: 5034-5036. 2014
• Ylikangas Henna, Malmioja Kalle, Peura Lauri, Gynther Mikko, Nwachukwu Emmanuel O, Leppänen Jukka, Laine Krista, Rautio Jarkko, Lahtela-Kakkonen Maija, Huttunen Kristiina M, Poso Antti. 2014. Quantitative Insight into the Design of Compounds Recognized by the L-Type Amino Acid Transporter 1 (LAT1). CHEMMEDCHEM 9: 2699-2707. 2014
• Gynther Mikko, Kääriäinen Tiina M, Hakkarainen Jenni J, Jalkanen Aaro J, Petsalo Aleksanteri, Lehtonen Marko, Peura Lauri, Kurkipuro Jere, Samaranayake Haritha, Yla-Herttuala Seppo, Rautio Jarkko, Forsberg Markus M. 2014. Brain Pharmacokinetics of Ganciclovir in Rats with Orthotopic BT4C Glioma. DRUG METABOLISM AND DISPOSITION 2015; 43: 140-146. 2014
• Rautio Jarkko, Gynther Mikko, Laine Krista. 2013. LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier?. Therapeutic Delivery 4 3: 281-284. 2013
• Huttunen Kristiina M, Leppänen Jukka, Laine Krista, Vepsäläinen Jouko, Rautio Jarkko. 2013. Convenient microwave-assisted synthesis of lipophilic sulfenamide prodrugs of metformin. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 49: 624-628. 2013
• Nevalainen Tapio, Poso Antti, Rautio Jarkko. 2013. Farmaseuttinen kemia - uudet haasteet Itä-Suomen yliopistossa: Ahonen R, Laitinen K, Lapinjoki S, Mensalo P, Ranta V-P, Ylikangas H (toim)., Muutosten vuosikymmen : Itä-Suomen yliopiston farmasian laitos 40 vuotta. Publications of the University of Eastern Finland. General Series 13. 34-42. 2013
• Peura Lauri, Malmioja Kalle, Huttunen Kristiina, Leppänen Jukka, Hämäläinen Miia, Forsberg Markus M, Gynther Mikko, Rautio Jarkko, Laine Krista. 2013. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine. PHARMACEUTICAL RESEARCH 30: 2523-2537. 2013
• Huttunen Kristiina M, Leppänen Jukka, Vepsäläinen Jouko, Sirviö Jouni, Laine Krista, Rautio Jarkko. 2012. In vitro and in vivo evaluation of a sulfenamide prodrug of basic metformin. JOURNAL OF PHARMACEUTICAL SCIENCES 101 8: 2854-2860. 2012
• Huttunen Kristiina M, Tani Niina, Juvonen Risto O, Raunio Hannu, Rautio Jarkko. 2012. Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome P450-activated prodrugs. Molecular Pharmaceutics 2013:10: 532-537. 2012
• Rautio Jarkko. 2012. Inhibitors of LRRK2 kinase activity to probe the treatment option in Parkinson's disease. JOURNAL OF MEDICINAL CHEMISTRY 55 22: 9414-9415. 2012
• Vig Balvinder S, Huttunen Kristiina M, Laine Krista, Rautio Jarkko. 2012. Amino acids as promoieties in prodrug design and development. ADVANCED DRUG DELIVERY REVIEWS 2013:65: 1370-1385. 2012
• Ylikangas Henna, Peura Lauri, Malmioja Kalle, Leppänen Jukka, Laine Krista, Poso Antti, Lahtela-Kakkonen Maija, Rautio Jarkko. 2012. Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 2013:48: 523-531. 2012
• Peura Lauri, Malmioja Kalle, Rautio Jarkko. 2011. Aihiolääketeknologia lääkekehityksessä. [Summary: Prodrug technology in the development of medicinal agents]. DUODECIM 127 3: 263-272. 2011
• Vig Balvinder, Rautio Jarkko. 2011. Amino acid prodrugs for oral delivery: challenges and opportunities. Therapeutic Delivery 2 8: 959-962. 2011
• Warren Mark S, Rautio Jarkko. 2011. Prodrugs designed to target transporters for oral drug delivery: Rautio Jarkko, Prodrugs and Targeted Delivery. Methods and Principles in Medicinal Chemistry 47. 231-252. 2011
• Prodrugs and Targeted Delivery: Towards Better ADME Properties. Rautio Jarkko. 2011 2011
• Rautio Jarkko. 2011. Prodrug strategies in drug design: Rautio Jarkko, Prodrugs and Targeted Delivery. Methods and Principles in Medicinal Chemistry 47. 3-30. 2011
• Peura Lauri, Malmioja Kalle, Laine Krista, Leppänen Jukka, Gynther Mikko, Isotalo Antti, Rautio Jarkko. 2011. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. Molecular Pharmaceutics 8 5: 1857-1866. 2011
• Kalle Malmioja, Lauri Peura, Krista Laine, Jukka Leppänen, Mikko Gynther, Jarkko Rautio. 2011. New Prodrug Design Ideas for Transporter-Mediated CNS Drug Delivery. Teoksessa: (toim.), Current Medicinal Chemistry Special Issue Abstracts. ss. 181. 2011
• Huttunen Kristiina, Raunio Hannu, Rautio Jarkko. 2011. Prodrugs - from serendipity to rational design. PHARMACOLOGICAL REVIEWS 63 3: 750 - 771. 2011
• Huttunen Kristiina M, Rautio Jarkko. 2011. Prodrugs - an efficient way to breach delivery and targeting barriers. CURRENT TOPICS IN MEDICINAL CHEMISTRY 11: 2265-2287. 2011
• Peura L, Malmioja K, Laine K, Leppänen J, Gynther M & Rautio J. 2011. New Prodrug Desing Ideas for Large Amino Acid Transporter 1 -Mediated Drug Brain Delivery, BioMedical Transporters 2011: Membrane Transporters in Drug Discovery. P30. 2011
• Gynther M, Jalkanen A, Lehtonen M, Forsberg M, Laine K, Ropponen J, Leppänen J, Knuuti J & Rautio J. 2010. Brain uptake of ketoprofen-lysine prodrug in rats. INTERNATIONAL JOURNAL OF PHARMACEUTICS 399: 121-128. 2010
• Rautio J, Leppänen J, Lehtonen M, Laine K, Koskinen M, Pystynen J, Savolainen J & Sairanen M. 2010. Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol-O-methyltransferase inhibitor. BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 20: 2614 - 2616. 2010
• Rautio Jarkko, Laine Krista, Fang Lanyan, Han Bing, Huttunen Kristiina, Sun Duxin. 2010. Enzyme-activated prodrug strategies for targeted drug action: Ram I. Mahato and Ajit S. Narang, Targeted Delivery of Small and Macromolecular Drugs.CRC Press, Taylor& Francis Group. 311-348. 2010
• Gynther M, Ropponen J, Laine K, Leppänen J, Haapakoski P, Peura L, Järvinen T, Rautio J. 2009. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats. JOURNAL OF MEDICINAL CHEMISTRY 52: 3348-3353. 2009
• Huttunen KM, Mannila A, Laine K, Kemppainen E, Leppänen J, Vepsäläinen J, Järvinen T, Rautio J. 2009. The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption. JOURNAL OF MEDICINAL CHEMISTRY 52: 4142-4148. 2009
• Huttunen KM, Rautio J, Leppänen J, Vepsäläinen J, Keski-Rahkonen P. 2009. Determination of metformin and its prodrugs in human and rat blood by hydrophilic interaction liquid chromatography. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 50: 469-474. 2009
• Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, Savolainen J. 2008. Prodrugs: design and clinical applications NATURE REVIEWS DRUG DISCOVERY 7: 255-270. 2008
• Rautio Jarkko, Laine Krista, Gynther Mikko, Savolainen Jouko. 2008. Prodrug approaches for CNS delivery. AAPS JOURNAL [ONLINE:HTTP://WWW.AAPSPHARMSCI.ORG/] 10: 92-102. 2008
• Rautio J, Laine K, Gynther M. 2008. Enhanced brain drug delivery and targeting. PHARMACEUTICAL TECHNOLOGY EUROPE 20 4: 27-33. 2008
• Huttunen KM, Mähönen N, Raunio H, Rautio J. 2008. Cytochrome P450-activated prodrugs: targeted drug delivery. CURRENT MEDICINAL CHEMISTRY (SCHIPHOL) 15 23: 2346-2365. 2008
• Kumpulainen H, Järvinen T, Mannila A, Leppänen J, Nevalainen T, Mäntylä A, Vepsäläinen J, Rautio J. 2008. Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 34: 110-117. 2008
• Kumpulainen E, Kokki H, Laisalmi M, Heikkinen M, Savolainen J, Rautio J, Lehtonen M. 2008. How readily does ketorolac penetrate cerebrospinal fluid in children?. JOURNAL OF CLINICAL PHARMACOLOGY 48: 495-501. 2008
• Kokki H, Kumpulainen E, Laisalmi M, Savolainen J, Rautio J, Lehtonen M. 2008. Diclofenac readily penetrates the cerebrospinal fluid in children. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 65 6: 879-884. 2008
• Gynther M, Laine K, Ropponen J, Leppänen J, Mannila A, Nevalainen T, Savolainen J, Järvinen T, Rautio J. 2008. Large neutral amino acid transporter enables brain drug delivery via prodrugs. JOURNAL OF MEDICINAL CHEMISTRY 51: 932-936. 2008
• Huttunen KM, Mähönen N, Leppänen J, Vepsäläinen J, Juvonen RO, Raunio H, Kumpulainen H, Järvinen T, Rautio J. 2007. Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality PHARMACEUTICAL RESEARCH 24 4: 679-687. 2007
• Kokki H, Kumpulainen E, Lehtonen M, Laisalmi M, Heikkinen M, Savolainen J, Rautio J. 2007. Cerebrospinal fluid distribution of ibuprofen after intravenous administration in children. PEDIATRICS [ONLINE] 120 4: e1002-e1008. 2007
• Mannila A, Kumpulainen E, Lehtonen M, Heikkinen M, Laisalmi M, Salo T, Rautio J, Savolainen J, Kokki H. 2007. Plasma and cerebrospinal fluid concentrations of indomethacin in children after intravenous administration. JOURNAL OF CLINICAL PHARMACOLOGY 47: 94-100. 2007
• Ribeiro L, Silva N, Iley J, Rautio J, Järvinen T, Hélder M-F, Moreira R, Mendes E. 2007. Aminocarbonyloxymethyl ester prodrugs of flufenamic acid and diclofenac: suppressing the rearrangement pathway in aqueous media. ARCHIV DER PHARMAZIE 340: 32-40. 2007
• Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. 2006. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates DRUG METABOLISM AND DISPOSITION 34 5: 786-792. 2006
• Sloan KB, Wasdo SC, Rautio J. 2006. Design for optimized topical delivery: prodrugs and a paradigm change. PHARMACEUTICAL RESEARCH 23 12: 2729-2747. 2006
• Huttunen KM, Kumpulainen H, Leppänen J, Rautio J, Järvinen T, Vepsäläinen J. 2006. Efficient strategy to prepare water-soluble prodrugs of ketones. SYNLETT 5: 701-704. 2006
• Kumpulainen H, Saari R, Lehtonen M, Rautio J, Järvinen T, Vepsäläinen J. 2006. Convenient microwave-assisted synthesis of 1-chloroethyl phosphates. TETRAHEDRON LETTERS 47: 2003-2004. 2006
• Kumpulainen H, Mähönen N, Laitinen M-L, Jaurakkajärvi M, Raunio H, Juvonen RO, Vepsäläinen J, Järvinen T, Rautio J. 2006. Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure. JOURNAL OF MEDICINAL CHEMISTRY 49: 1207-1211. 2006
• Mannila A, Rautio J, Lehtonen M, Järvinen T, Savolainen J. 2005. Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 24: 101-105. 2005
• Mäntylä A, Garnier T, Rautio J, Nevalainen T, Vepsäläinen J, Koskinen A, Croft SL, Järvinen T. 2004. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. JOURNAL OF MEDICINAL CHEMISTRY 47: 188-195. 2004
• Mäntylä A, Rautio J, Nevalainen T, Keski-Rahkonen P, Vepsäläinen J, Järvinen T. 2004. Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 23: 151-158. 2004
• Mäntylä A, Rautio J, Nevalainen T, Vepsälainen J, Juvonen R, Kendrick H, Garnier T, Croft SL, Järvinen T. 2004. Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives. BIOORGANIC AND MEDICINAL CHEMISTRY 12: 3497-3502. 2004
• Näsi E, Rautio J. 2004. Lääkeaineiden ihonläpäisevyyttä parantavat menetelmät. DOSIS : FARMASEUTTINEN AIKAKAUSKIRJA 20 3: 209-222. 2004
• Rautio J, Chikhale PJ. 2004. Drug delivery systems for brain tumor therapy. CURRENT PHARMACEUTICAL DESIGN 10: 1341-1353. 2004
• Tolle-Sander S, Rautio J, Wring S, Polli JW, Polli JE. 2003. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. PHARMACEUTICAL RESEARCH 20 5: 757-764. 2003
• Savolainen J, Rautio J, Razzetti R, Järvinen T. 2003. A novel D2-dopaminergic and alfa2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits. JOURNAL OF PHARMACY AND PHARMACOLOGY 55: 789-794. 2003
• Järvinen T, Rautio J, Nevalainen T, Taipale H, Vepsäläinen J, Gynther J. 2003. Ei-steroidaalisten anti-inflammatoristen karboksyylihappojen aihiolääkkeitä sisältävät farmaseuttiset koostumukset topikaaliseen käyttöön. FI 110921 B. Suomi. 2003
• Mendes E, Furtado T, Neres J, Iley J, Jarvinen T, Rautio J, Moreira R. 2002. Synthesis, stability and in vitro dermal evaluation of aminocarbonyloxymethyl esters as prodrugs of carboxylic acid agents. BIOORGANIC AND MEDICINAL CHEMISTRY 10: 809-816. 2002
• Rautio J, Nevalainen T, Taipale H, Vepsäläinen J, Gynther J, Laine K, Järvinen T. 2000. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 11: 157-163. 2000
• Rautio J, Nevalainen T, Taipale H, Vepsäläinen J, Gynther J, Laine K, Järvinen T. 2000. Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (naproxen) for topical drug delivery JOURNAL OF MEDICINAL CHEMISTRY 43 8: 1489-1494. 2000
• Rautio J. 2000. Aihiolääkkeet parantavat lääkeaineen ihonläpäisevyyttä DOSIS : FARMASEUTTINEN AIKAKAUSKIRJA 16 4: 314-317. 2000
• Rautio J. 2000. Synthesis and in Vitro Evaluation of Novel Naproxen and Ketoprofen Prodrugs for Topical Drug Delivery. Kuopion yliopiston julkaisuja A. Farmaseuttiset tieteet. 2000
• Rautio J, Nevalainen T, Taipale H, Vepsäläinen J, Gynther J, Pedersen T, Järvinen T. 1999. Synthesis and in vitro evaluation of aminoacyloxyalkyl esters of 2-(6-methoxy-2-naphthyl) propionic acid as novel naproxen prodrugs for dermal drug delivery. PHARMACEUTICAL RESEARCH 16 8: 1172-1178. 1999
• Rautio J, Taipale H, Gynther J, Vepsäläinen J, Nevalainen T, Järvinen T. 1998. In vitro evaluation of acyloxyalkyl esters as dermal prodrugs of ketoprofen and naproxen. JOURNAL OF PHARMACEUTICAL SCIENCES 87 12: 1622-1628. 1998
• Järvinen T, Rautio J, Niemi R. 1997. Aihiolääkkeet. DUODECIM 113: 2564-2568. 1997
• Rautio J, Taipale H, Järvinen T. 1997. Voidaanko aihiolääkkeillä parantaa lääkeaineen ihonläpäisyä?. DOSIS : FARMASEUTTINEN AIKAKAUSKIRJA 13 1: 11-21. 1997